WO/2005/019168 is referenced by 40 patents.

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV ('DPP-IV')of formula (Ia) and (Ib), pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes, metabolic syndrome (syndrome X or insulin resistance syndrome), hyperglycemia, impaired glucose tolerance, glucosuria, metabolic acidosis, arthritis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes.

Fluorinated lysine derivatives as dipeptidyl peptidase iv inhibitors
Application Number
Publication Number
Application Date
August 10, 2004
Publication Date
March 3, 2005
Parker Janice C
Hulin Bernard
FULLER Grover F Jr
Parker Janice C
Hulin Bernard
Pfizer Products
C07D 413/12
C07D 409/12
C07D 405/12
C07D 403/12
C07D 401/12
C07D 207/10
View Original Source